相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Muscarinic M1 receptor agonists: can they improve cognitive performance?
Elizabeth Scarr
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia - A path model investigation
Jan-Henry Stenberg et al.
NEUROPHARMACOLOGY (2013)
Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain
Linda Scoriels et al.
NEUROPHARMACOLOGY (2013)
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia
Jeffrey A. Lieberman et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Antiherpes Virus-Specific Treatment and Cognition in Schizophrenia: A Test-of-Concept Randomized Double-Blind Placebo-Controlled Trial
Konasale M. Prasad et al.
SCHIZOPHRENIA BULLETIN (2013)
Short-Term Tropisetron Treatment and Cognitive and P50 Auditory Gating Deficits in Schizophrenia
Xiang Yang Zhang et al.
AMERICAN JOURNAL OF PSYCHIATRY (2012)
Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence
Mario Fioravanti et al.
BMC PSYCHIATRY (2012)
Phencyclidine/Schizophrenia: One View Toward the Past, The Other to the Future
Edward F. Domino et al.
SCHIZOPHRENIA BULLETIN (2012)
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
Robert W. Buchanan et al.
BIOLOGICAL PSYCHIATRY (2011)
The treatment of cognitive impairment in schizophrenia
Donald C. Goff et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial
Sung Joon Cho et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Richard J. Radek et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder: An 8-Week, Double-Blind, Randomized, Controlled, 2-Center, Parallel-Group Trial
Michael S. Ritsner et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
High dose D-serine in the treatment of schizophrenia
Joshua T. Kantrowitz et al.
SCHIZOPHRENIA RESEARCH (2010)
Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial
Shahin Akhondzadeh et al.
SCHIZOPHRENIA RESEARCH (2009)
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
David A. Lewis et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
Michael Berk et al.
BIOLOGICAL PSYCHIATRY (2008)
Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
Donald C. Goff et al.
SCHIZOPHRENIA RESEARCH (2008)
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
Ruth S. Barr et al.
NEUROPSYCHOPHARMACOLOGY (2008)
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
Donald C. Goff et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
Suzie Lavoie et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia - Is it a practice effect?
Terry E. Goldberg et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia:: A randomized, double-blind, placebo-controlled study
Tomiki Sumiyoshi et al.
SCHIZOPHRENIA RESEARCH (2007)
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison
Richard S. E. Keefe et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
Mark S. George et al.
SCHIZOPHRENIA RESEARCH (2007)
A 12-week, double-blind, ptacebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
Bong-Ju Lee et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial
Richard S. E. Keefe et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics, for the cognitive impairments in chronic schizophrenia
Sae-Woom Lee et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2007)
Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits
Sylvie Chouinard et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Effects of γ-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia
Lara Menzies et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia - A randomized, double-blind, placebo-controlled, crossover trial
Michael S. Ritsner et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Galantamine improves cognition in schizophrenic patients stabilized on risperidone
Max H. Schubert et al.
BIOLOGICAL PSYCHIATRY (2006)
Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation
Tonmoy Sharma et al.
SCHIZOPHRENIA RESEARCH (2006)
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers
DM Barch et al.
SCHIZOPHRENIA RESEARCH (2005)
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
O Freudenreich et al.
PSYCHOPHARMACOLOGY (2005)
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
MF Green et al.
SCHIZOPHRENIA RESEARCH (2004)
Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia
SR Marder et al.
SCHIZOPHRENIA RESEARCH (2004)
Serotonin receptors : their key role in drugs to treat schizophrenia
HY Meltzer et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
T Sumiyoshi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
DC Goff et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
T Sumiyoshi et al.
BIOLOGICAL PSYCHIATRY (2001)
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist
JE Macor et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Glutamate receptor expression in schizophrenic brain
JH Meador-Woodruff et al.
BRAIN RESEARCH REVIEWS (2000)
D-1 receptors in prefrontal cells and circuits
PS Goldman-Rakic et al.
BRAIN RESEARCH REVIEWS (2000)
分享论文
